作者: Victoria P.Y. Tan , Benjamin C.Y. Wong
DOI: 10.1016/J.GTC.2013.02.001
关键词:
摘要: Chemoprevention may form the cornerstone in management of gastric adenocarcinoma future. Helicobacter pylori eradication and aspirin and/or nonsteroidal anti-inflammatory drug therapy have emerged as front-runner chemotherapeutic agents due to putative pathogenic mechanisms that they address. Before a population-based chemopreventive strategy can be recommended on large scale, randomized controlled trials with follow-up more than 10 years these 2 populations at high risk is urgently awaited.